Showing results (581-590 of 605) with videos related to

Sort By:
Pageof 61
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2021
Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort StudyJingge Qu, Mengtao Li, Yanhong Wang, et al.
Respiratory Research|September 9, 2023
A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort studyJingge Qu, Mengtao Li, Xiao Zhang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 20, 2026
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 TrialPhilip J Mease, Vinod Chandran, April W Armstrong, et al.
Medcomm|November 17, 2025
Applying Genetic Risk Score to Improve Risk Assessment of New-Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large-Scale Prospective Cohort StudyYufang Ding, Mucong Li, Wei Bai, et al.
RMD Open|November 23, 2023
Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosusHanxiao You, Jiuliang Zhao, Miaojia Zhang, et al.
Rheumatology (Oxford, England)|February 27, 2016
Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patientsChen Li, Yuzhi Zuo, Nan Wu, et al.
RMD Open|March 8, 2024
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD ConsortiumLinyi Peng, Jingna Li, Jiaxin Zhou, et al.
Rheumatology and Immunology Research|January 13, 2025
Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 updateXinping Tian, Qian Wang, Nan Jiang, et al.
Journal of Ethnopharmacology|August 15, 2025
Efficacy of Qingrehuoxue granule for bone protection in patients with active rheumatoid arthritis in China: The PRE-ERODE randomized controlled trialXun Gong, Jing Kang, Tian Chang, et al.
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Pageof 61